FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
This important study provides data supporting the efficacy of adjuvant chemotherapy specific to the upper tract urothelial carcinoma stetting. The authors correctly point out the limitations inherent to retrospective observational studies but make the case that adjuvant chemotherapy should be considered in patients with pT3/T4 and/or pN+ upper tract urothelial carcinoma pending level I evidence.
Read the Abstract
Author: Bishoy M. Faltas MD
Seisen T, Krasnow RE, Bellmunt J, Rouprêt M, Leow JJ, Lipsitz SR, Vetterlein MW, Preston MA, Hanna N, Kibel AS, Sun M, Choueiri TK, Trinh QD, Chang SL. Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. J Clin Oncol. 2017 Jan 3:JCO2016694141. [Epub ahead of print]